A Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Voluneteers
Overview
The purpose of this study is to determine the effects of NGX426 on intradermal capsaicin induced pain in hyperalgesia.
Full Title of Study: “A Double-Blind, Randomized, Placebo Controlled, Cross-Over, Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Volunteers”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Treatment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Study Primary Completion Date: September 2008
Interventions
- Drug: Placebo
- Drug: Oral NGX426 (Powder in solution)
Arms, Groups and Cohorts
- Placebo Comparator: 1
- Placebo
- Experimental: 2
- Powder in solution
- Experimental: 3
Participating in This Clinical Trial
Inclusion Criteria
- Healthy males, age 21-55 Exclusion Criteria:
- Allergy to study drug
Gender Eligibility: Male
Minimum Age: 21 Years
Maximum Age: 55 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- TorreyPines Therapeutics
- Provider of Information About this Clinical Study
- Susan Mellberg, R.N., M.B.A.; VP, Project Management, TorreyPines Therapeutics, Inc.
- Overall Official(s)
- Mark Wallace, M.D., Principal Investigator, University of California, San Diego
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.